Authored by 
Reviewed by Gabapentin has become a prevalent off-label option for various medical conditions. The prevalence of Neurontin prescribing among the U.S. privately insured population has increased steadily in recent years, with estimates of off-label prescribing as high as 95%. Considering how widely used this medication is, it pays to know a little more about this medication, including how long the medication stays in your system.
Table Of Contents:
How long Gabapentin stays in Your System?
Gabapentin is not generally tested in a typical drug test. The substance can be detected if instructions are made to look for the presence of the drug mainly. As the medicine remains in your urine, blood, saliva, and hair for a different amount of time. The detectability of the drug varies in different test types and according to other factors mentioned above.
How long does Gabapentin stay In Your Blood?
It stays till five to seven hours after use; hence the detectability of neurontin will range from five to seven hours. However, the drug takes up to two days to clean from the blood as the drug is not protein-bound.
How long does Gabapentin stay In Your Saliva?
It stays within a few hours or till a day. Saliva quickly detects a drug even within just minutes of usage. Although the route of administration of this medicine is oral, the salivas swab test cannot quickly assist in indicating Neurontin in the system.
How long does Gabapentin stay In Your Hair?
The amount of drug present in someone’s hair follicles can be traced through hair tests. However, it is unusual to use a hair test in determining Neurontin. The presence of most drugs can be detected up to 90 days of use in hair samples. The reason being, there is no way to tamper with the drug content in someone’s hair. However, usually, hair shows less practical results.
How long does Gabapentin stay In Your Urine?
Urine test is the most common method to test the presence of this drug because they are easy to administer and provide rapid results. Urinalysis can detect the drug for up to two to three days.
Moreover, According to a study approved by the Essex Institutional Review Board, a total of 57,542 urine specimens of chronic pain patients from 231 different pain clinics which were located in 19 states were examined over the period of November 2009, to May 2010. The Neurontin prevalence was 12.2% as it was identified in 7013 specimens.
Gabapentin Half-Life
This medication can stay for up to two days after intake. Its half-life is between five and seven hours. In general, it will be completely out of the system within 48 hours, but, in some cases, a half-life of 132 hours has also been reported (after a dose of 400 mg).
Gabapentin Metabolism: How Is It Metabolized?
Gabapentin is eliminated from the systemic circulation by renal excretion as an unchanged medication. Neurontin is not appreciably metabolized in humans. Metabolites account for less than 1% of an administered dose.
The remainder is excreted as unchanged parent drug in the urine. In elderly patients and/or patients with impaired renal function, Neurontin plasma clearance is reduced. Neurontin can be removed from the plasma by hemodialysis.
Factors That Influence Gabapentin Elimination
Even health experts can’t say how long it takes for Neurontin to exit a user’s system, only because many factors affect the duration and the elimination of the drug:
- Drug Dosage and Use: Dose, poly-drug use, and history of abuse
- Health status: medical condition, and overall health.
- Individual Features (BMI): Age, Weight, height, and body fat
- Patients Lifestyle:Food intake, hydration, and exercising
Patients in the following categories may have problems with taking the drug and their excretion time from the body also varies. The details for each category is as follows:
Elderly Patients
Aging changes the way the bodies metabolize medications, with older individuals experiencing longer elimination times than younger ones. Like in older (over 65) and thinner patients, Gabapentin lingers longer.
Moreover, as numerous adults generally have a higher level of body fat as compared to muscle, this medication can be more concentrated in the body than it would be in younger patients.
Pediatric Patients
Neurontin is used in the treatment of partial seizures in pediatric patients aged between 3 – 12 years. It is prescribed mainly because it helps children to feel less pain.
Normally, the half-life for pediatric patients is 4.7 hours. This approximation modifies due to numerous variables included but not restricted to kidney function.
Adult Patients with Reduced Kidney Function
For grown-ups with renal weakening, the half-life can differ excessively, from 6.5 hours to 52 hours, relying upon the kidney function. The half-life of the drug in individuals having kidney disease can be more than seven times longer than in individuals without it.
Anuric Adult Patients
In case of renal dysfunction, the user might need more time to get clean. In patients who suffer from renal failure, it might take up to 30 days.
Essential Points to Remember Before Using Gabapentin
Understanding Neurontin half-life can help you understand how this medication can impact one’s body.
Gabapentin warnings to remember include:
- It usually remains in one’s system till two days after consumption.
- The most common drug detection way to check if Neurontin is still in your system is urinalysis.
- Neurontin can affect people differently depending on some variables like health, age, weight, and genetics.
- Even though the medication cannot be appreciably metabolized, It can be removed from plasma through hemodialysis.
- Despite the fact that the drug is sold without a prescription, there is the possibility of od on gabapentin.
It is not a controlled drug, but this medication can still be abused. If you or a loved one needs help to weaning off gabapentin, addiction, or withdrawal symptoms, rehabilitation centers help as an excellent option to get this medical treatment.
Page Sources
- J Manag Care Spec Pharm, Trends in Gabapentin Prescribing in a Commercially Insured U.S. Adult Population, 2009-2016, 2020 Mar, https://www.jmcp.org/doi/full/10.18553/jmcp.2020.26.3.246
- Harvard Health Publishing, Drugs that relieve nerve pain, August 29, 2020, https://www.health.harvard.edu/pain/drugs-that-relieve-nerve-pain
- Alyssa M Peckham, Kirk E Evoy, Leslie Ochs, and Jordan R Covvey, Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?, 2018, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153543/
- Pfizer, NEURONTIN (gabapentin), FULL PRESCRIBING INFORMATION, 2020 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020235s068,020882s049,021129s049lbl.pdf
- Bryant Ranch Prepack, GABAPENTIN- gabapentin capsule, Revised: 7/2020, https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/506bf880-9564-404c-951a-703797ffdad8/spl-doc?hl=gabapentin%7CBryant%20Ranch%20Prepack
- Parke-Davis Div of Pfizer Inc, DRUG LABEL INFORMATION, Updated April 14, 2020, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388
- Nathan Arnold, Media Inquiries, FDA In Brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression, December 19, https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression
- Chelsea C. McDonnell, When GABA Goes From Fab One Day to Drab the Next: Safety of gabapentinoids in combination with opioids, 11 October 2019, https://sites.utexas.edu/pharmacotherapy-rounds/files/2019/10/McDonnell-ResRounds-Handout-without-pic-Oct-2019.pdf
- Jamie L. Fleet, Stephanie N. Dixon, Paul John Kuwornu, Varun K. Dev, Manuel Montero-Odasso, and Amit X. Garg, Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study, 2018, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851574/
- Abigail Lyndon, Suzanne Audrey, Claudia Wells, Erica S Burnell, Suzanne Ingle, Rob Hill, Matthew Hickman, and Graeme Henderson, Risk to heroin users of poly-drug use of pregabalin or gabapentin, 2017, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635829/
- Rebecca Heltsley, Anne DePriest, David L. Black, Tim Robert, Yale H. Caplan3, and Edward J. Cone, Urine DrugTesting of Chronic Pain Patients. IV. Prevalence of Gabapentin and Pregabalin, 2011, https://www.researchgate.net/publication/51478342_Urine_Drug_Testing_of_Chronic_Pain_Patients_IV_Prevalence_of_Gabapentin_and_Pregabalin